

Using information to improve quality & choice

NCIN service profiles – a short overview

Nicky Coombes Service Profiles Programme Manager



The National Cancer Intelligence Network will be hosted by Public Health England from 1st April 2013

National Cancer Peer Review




Using information to improve quality & choice


Publication of national Peer Review report including Urology specific chapter:

For example...









	PCT Name	updated	Year	East of England	Bedfordshire	Cambridgeshire	East & North Hertfordshire	Great Yarmouth &	Luton	Mid Essex	Norfolk	North East Fssex	Peterborough	South East Essex	South West Essex	Suffolk	West Essex	Vest Hertfordshire
saving	Percentage of eligible children in Reception with height and weight measurements	Y	2007/08	87.9	93.6	87.1	85.0	86.1	91.1	75.7	90.9	89.1	89.5	84.2	90.0	90.3	912	86.6
lives s	Percentage of obese children in Reception	Y	2007/08	9.3	8.7	8.9	8.7	10.4	12.5	8.7	9.1	9.0	12.6	8.3	10.8	8.8	8.2	8.8
Improving lives sar	Percentage of eligible children in Year 6 with height and weight measurements	Y	2007/08	84.0	86.9	83.2	86.8	89.7	92.9	69.4	86.5	80.3	67.0	83.2	87.4	85.7	86.5	85.6
, and the second	Percentage of obese children in Year 6	Y	2007/08	16.7	15.1	17.0	16.3	19.6	20.5	15.7	18.0	15.9	19.1	16.8	17.5	14.4	17.6	15.2
	Percentage of women smoking at delivery	Y	2007/08	14.3	19.6	11.6	14.0	DNR	17.6	10.5	13.1	20.8	16.1	14.0	11.2	13.8	14.4	14.0
Child Health	Percentage of maternities with known smoking status	Y	2007/08	98.2	95.8	100.0	100.0	DNR	96.0	95.1	95.5	99.7	100.0	98.8	98.6	99.1	97.2	100.0
Child	Percentage of mothers known to initiate breastfeeding"	Y	2007/08	73.0	65,3	79.0	73.8	68,1	DNR	DNR	73.8	73.9	67.5	70.3	69.8	73.9	75.8	76.0
	Percentage of maternities with known breastfeeding status	Y	2007/08	98.1	95.2	100.0	99.0	97.6	DNR	DNR	95.2	99.9	100.0	97.8	98.1			99.3
Serual		Y	2008/09 G2	1364	1188	1224	466											
Se	Teenage conception rates per 1,000 females aged 15-17		2004-06	32.8	32.5				Т	-	r	+		n	r			C
E is		Y	2007/08	84	85.7	84.0				0		L				ų	y	3



Profiles...



Certain Contract of the second	dicator umber of newly diagnosed lung cancer patients per year, 2010 [experimental] (1) umber of NLCA patients - lung cancer umber of NLCA patients - mesothelioma atients (from #1) aged 70+ atients (from #1) with recorded ethnicity atients (from #1) with recorded ethnicity atients (from #1) who are Income Deprived (2) ale patients (from #1) umber and proportion of patients, excluding SCLC, with a stage lor II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned es review: Does the specialist team have full membership? (3) eser review: Proportion of per review indicators met	No. of patients/ cases or value 304 329 111 188 295 33 161 326 83 36 161 326 83 36 167 286 SAA	Trust 62% 97% 1% 29% 29% 29% 29% 13% 58% 87% 87%	Percentar Lower 95% confidence limit 56% 94% 0% 94% 0% 24% 97% 24% 95% 83%	Upper 95% confidence limit 67% 98% 3% 3% 58% 100% 35% 100% 35% 64%	England 2007 1911 10 61% 93% 7% 16% 55% 92% 24% 24% 14% 62%	Low- est 41 1 0 39% 66% 0% 7% 43% 36% 10% 4%	ust rate or percentage compared to Engl	High- est 588 585 31 75% 100% 46% 34% 100% 68%	Source NCDR NLCA NCDR NCDR NCDR NCDR NCDR NCDR NCDR	Period 2010 2011 2011 2010 2010 2010 2010 2011 2011
Size 2 3 Num 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2	umber of NLCA patients - lung cancer umber of NLCA patients - mesothelioma atients (from #1) aged 70+ atients (from #1) with recorded ethnicity atients (from #1) who are Income Deprived (2) ale patients (from #1) umber and proportion of patients (from #2) with a stage assigned umber and proportion of patients, excluding SCLC, with stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned a	329 11 188 295 3 161 326 83 36 167 286 SA	97% 1% 29% 53% 99% 29% 13% 58% 87%	94% 0% 47% 97% 24% 9% 53%	98% 3% 58% 100% 35% 17% 64%	191 10 61% 93% 7% 16% 55% 92% 24% 14%	1 0 39% 66% 0% 7% 43% 36% 10%		585 31 75% 100% 46% 34% 72% 100%	NLCA NLCA NCDR NCDR NCDR NCDR NCDR NLCA	2011 2011 2010 2010 2010 2010 2010 2011
3 Num 4 Pati 5 Pati 6 period 6 period 6 period 9 period 9 period 9 period 9 period 9 period 9 period 10 perio	umber of NLCA patients - mesothelioma atients (from #1) with recorded ethnicity atients (from #1) with recorded ethnicity which is not White-British atients (from #1) who are Income Deprived (2) ale patients (from #1) umber and proportion of patients (from #2) with a stage assigned umber and proportion of patients, excluding SCLC, with stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned orportion of patients (from #2) with a Performance Status assigned eer review: Does the specialist team have full membership? (3)	11 188 295 3 161 326 36 167 286 SA	97% 1% 29% 53% 99% 29% 13% 58% 87%	94% 0% 47% 97% 24% 9% 53%	98% 3% 58% 100% 35% 17% 64%	10 61% 93% 7% 16% 55% 92% 24% 14%	66% 0% 7% 43% 36% 10%		31 75% 100% 46% 34% 72% 100%	NLCA NCDR NCDR NCDR NCDR NCDR NLCA	2011 2010 2010 2010 2010 2010 2010 2011
Consider the second sec	atients (from #1) aged 70+ atients (from #1) with recorded ethnicity atients (from #5) with recorded ethnicity which is not White-British atients (from #1) who are Income Deprived (2) ale patients (from #1) umber and proportion of patients, excluding SCLC, with a stage assigned umber and proportion of patients, excluding SCLC, with a stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned coportion of patients, (from #2) with a Performance Status assigned are review: Does the specialist team have full membership? (3)	188 295 3 161 326 83 36 167 286 SA	97% 1% 29% 53% 99% 29% 13% 58% 87%	94% 0% 47% 97% 24% 9% 53%	98% 3% 58% 100% 35% 17% 64%	61% 93% 7% 16% 55% 92% 24% 14%	66% 0% 7% 43% 36% 10%		100% 46% 34% 72% 100%	NCDR NCDR NCDR NCDR NCDR NLCA	2010 2010 2010 2010 2010 2010 2011
Central Control of Con	atients (from #1) with recorded ethnicity atients (from #5) with recorded ethnicity which is not White-British atients (from #1) who are Income Deprived (2) ale patients (from #1) umber and proportion of patients (from #2) with a stage assigned umber and proportion of patients, excluding SCLC, with a stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned aumber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned aumber and proportion of patients, excluding SCLC, status assigned action of patients (from #2) with a Performance Status assigned action exclusions and proper the specialist team have full membership? (3)	295 3 161 326 83 36 167 286 SA	97% 1% 29% 53% 99% 29% 13% 58% 87%	94% 0% 47% 97% 24% 9% 53%	98% 3% 58% 100% 35% 17% 64%	93% 7% 16% 55% 92% 24% 14%	66% 0% 7% 43% 36% 10%		100% 46% 34% 72% 100%	NCDR NCDR NCDR NCDR NLCA	2010 2010 2010 2010 2010 2011
Demographics De	atients (from #5) with recorded ethnicity which is not White-British atients (from #1) who are Income Deprived (2) ale patients (from #1) umber and proportion of patients, (from #2) with a stage assigned umber and proportion of patients, excluding SCLC, with stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned er review: Does the specialist team have full membership? (3)	3 161 326 83 36 167 286 SA	1% 29% 53% 99% 29% 13% 58% 87%	0% 47% 97% 24% 9% 53%	3% 58% 100% 35% 17% 64%	7% 16% 55% 92% 24% 14%	0% 7% 43% 36% 10%		46% 34% 72% 100%	NCDR NCDR NCDR NLCA	2010 2010 2010 2011
Specialist	atients (from #1) who are Income Deprived (2) ale patients (from #1) umber and proportion of patients (from #2) with a stage assigned umber and proportion of patients, excluding SCLC, with a stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned coportion of patients (from #2) with a Performance Status assigned eer review: Does the specialist team have full membership? (3)	326 83 36 167 286 SA	29% 53% 99% 29% 13% 58% 87%	47% 97% 24% 9% 53%	58% 100% 35% 17% 64%	16% 55% 92% 24% 14%	7% 43% 36% 10%		34% 72% 100%	NCDR NCDR NLCA	2010 2010 2011
Specialist	ale patients (from #1) umber and proportion of patients (from #2) with a stage assigned umber and proportion of patients, excluding SCLC, with stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned oportion of patients (from #2) with a Performance Status assigned er review: Does the specialist team have full membership? (3)	326 83 36 167 286 SA	53% 99% 29% 13% 58% 87%	97% 24% 9% 53%	100% 35% 17% 64%	55% 92% 24% 14%	43% 36% 10%		72% 100%	NCDR NLCA	2010 2011
Specialist	umber and proportion of patients (from #2) with a stage assigned umber and proportion of patients, excluding SCLC, with stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned coportion of patients (from #2) with a Performance Status assigned er review: Does the specialist team have full membership? (3)	326 83 36 167 286 SA	99% 29% 13% 58% 87%	97% 24% 9% 53%	100% 35% 17% 64%	92% 24% 14%	36% 10%	• •	100%	NLCA	2011
Specialist	umber and proportion of patients, excluding SCLC, with stage I or II assigned umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned roportion of patients (from #2) with a Performance Status assigned eer review: Does the specialist team have full membership? (3)	83 36 167 286 SA	29% 13% 58% 87%	24% 9% 53%	35% 17% 64%	24% 14%	10%	• •			
Specialist	umber and proportion of patients, excluding SCLC, with a stage IIIA assigned umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned roportion of patients (from #2) with a Performance Status assigned eer review: Does the specialist team have full membership? (3)	36 167 286 SA	13% 58% 87%	9% 53%	17% 64%	14%			68%	NIL O A	2011
Specialist	umber and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned roportion of patients (from #2) with a Performance Status assigned eer review: Does the specialist team have full membership? (3)	167 286 SA	58% 87%	53%	64%		4%		5070	NLCA	2011
12 Nun 13 Prop 14 Pee 15 Pee	roportion of patients (from #2) with a Performance Status assigned eer review: Does the specialist team have full membership? (3)	286 SA	87%			62%			30%	NLCA	2011
14 Pee 15 Pee	eer review. Does the specialist team have full membership? (3)	SA		83%			13%		80%	NLCA	2011
Specialist 15 Pee			Yes		90%	89%	2%		100%	NLCA	2011
Specialist	eer review: Proportion of peer review indicators met		100							NCPR	2010/11
Specialist		SA	85%			89%				NCPR	2010/11
Team ¹⁶ Pee	eer review: are there immediate risks? (4)	SA	No							NCPR	2010/11
17 Pee	eer review: are there serious concerns? (4)	SA	No							NCPR	2010/11
18 Nun	umber and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	79%	0%	•	100%	NLCA	2011
19 Num	umber of urgent GP referrals for suspected cancer	406				293	0	• •	853	CWT	2010/11
20 Num	umber and proportion of patients (from #2) with confirmed NSCLC	184	56%	52%	60%	62%	0%	•	93%	NLCA	2011
Throughput 21 Num	umber and proportion of patients (from #2) with confirmed SCLC	40	12%	9%	16%	12%	0%	•	100%	NLCA	2011
and pathology 22 Num	umber and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	21	11%	8%	17%	19%	0%	•	79%	NLCA	2011
23 Nun	umber and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%	• •	100%	NLCA	2011
24 Esti	stimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%	 O 	97%	HES	2011
25 Q2 2	2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%		100%	CWT	2012/13 Q2
26 Q2 3	2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%		100%	CWT	2012/13 Q2
Waiting times 27 Urg	rgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%	•	46%	CWT	2011/12
-	ases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12
29 Q2 3	2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%	◆	100%	CWT	2012/13 Q2
30 No.	o. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	• •	100%	NLCA	2011
31 No.	o. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%	•	38%	NLCA	2011
32 No.	o. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%	• 0	45%	NLCA	2011
Practice 33 No.	o. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease	40	48%	38%	59%	53%	0%		100%	NLCA	2011
	o. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011
	o. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011
36 First	rst outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%	•	68%	PBR SUS	2011/12
Outcomes 37 NI C	LCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57		1.49	NLCA	2011
and Recovery	LCA: Proportion of patients surviving at one year and adjusted olds ratio of surviving 1 year	34%	1.43		2.11	1.0	0.40	Ť.	2.67	NLCA	2011
	atients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a	0.01	2.11	83%	66%	•	100%	CPES	2011/12
Experience - 40	% Red	13	n/a			00 /0	0%	·	78%	CPES	2011/12
CPES (8) 41 Num	umber of survey questions and % of those questions scoring red and green (7)	0	n/a				0%		69%	CPES	2011/12

Profiles... why?



			F		Percenta	ge or rate		Tr	ust rate or percentage compared to Eng	land		
Section	#	Indicator	No. of patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41	• • •	588	NCDR	2010
Size		Number of NLCA patients - lung cancer	329				191	1		585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0		31	NLCA	2011
		Patients (from #1) aged 70+ Patients (from #1) with recorded ethnicity	188 295	62% 97%	56% 94%	67% 98%	61% 93%	39% 66%		75%	NCDR	2010 2010
010)	6	Patients (from #5) with recorded ethnicity which is not White-British	295	97%	94%	3%	93%	0%	•	100% 46%	NCDR NCDR	2010
Demographics (based on newly gnosed patients, 2010)	7	Patients (from #1) who are Income Deprived (2)	3	29%	0 76	5 76	16%	7%	•	34%	NCDR	2010
aph ner tient	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010
ogr ed or	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	• •	100%	NLCA	2011
emo	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011
agu (F)	11	Number a							1 I		NLCA	2011
â	12	Number a					_	_		_	NLCA	2011
	13	Proportion Peer revie • Assess and benchmark	(av	vid	o ra	nde	of	inf	formation at	_	NLCA	2011
	14	Peer revie A33C33 and DChomman			G I a	nge			ormation at		NCPR	2010/11
Specialist		Peer revie									NCPR	2010/11
Team											NCPR	2010/11
		Number organisation level									NCPR	2010/11
	_									-	NLCA	2011
		Number c								-	CWT	2010/11
Throughput	20	Number a Allowe o (ot o glopoo' o					_	_	and the set of the set	-	NLCA	2011 2011
and	22		sse:	ssn	neni	t ot :	an	or	danisation	-	NLCA NLCA	2011
pathology								· · ·	J	-	NLCA	2011
	24	Estimatec								-	HES	2011
		Q2 2012/								-	CWT	2012/13 Q2
										-	CWT	2012/13 Q2
Waiting times	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%		46%	CWT	2011/12
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%	• •	100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	• •	100%	NLCA	2011
		No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%	•••	38%	NLCA	2011
Practice		No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%		45%	NLCA	2011
	33		40	48%	38%	59%	53%	0%		100%	NLCA	2011
	34 35		27 28	68% 58%	52% 44%	80% 71%	68% 55%	0%		100% 100%	NLCA NLCA	2011 2011
			28	58% 41%	44%	41%	32%	15%		100% 68%	PBR SUS	2011 2011/12
Outcomes			23,053	0.95	0.82		32%	0.57		1.49	NLCA	2011/12
			34%	1.43	0.82	2.11	1.0	0.37		2.67	NLCA	
and Recovery		NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year										
and Recovery	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year Patients surveyed & % reporting always being treated with respect & dignity (6)					83%	66%	•	_	CPES	2011
	38		13	n/a n/a			83%	66% 0%	•	100% 78%	CPES CPES	

Profiles – process



- Aim: Benchmark and assess trust/MDT for commissioning & clinical review
- Developed from similar Breast/Colorectal/Lung profiles published Dec 2011, Feb 2013)
- Data cancer registry, CWT, Audit, CPES, HES, Peer Review
- Routinely collected no extra burden on clinical teams
- Roughly half indicators generic, half specialist.
- Specialist indicators largely drawn from Audit and Clinical Lines of Enquiry
- A NCIN /KIT partnership
- Hosted in the Cancer Commissioning Toolkit
- www.cancertoolkit.org.uk

Profile anatomy



					Percenta	ge or rate		Tr	ust rate or percentage compared to Engl	and		
Section	#	Indicator	patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				20	41	• O	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				19	1	• 0	585	NLCA	2011
	3		11				10	0	•0	31	NLCA	2011
•	4		188	62%	56%	67%	61%	39%		75%	NCDR	2010
aphics newly ients, 2010)	5		295	97%	94%	98%	93%	66%	()	100%	NCDR	2010
50 A	6		3	1%	0%	3%	7%	0%	•	46%	NCDR	2010
Demographics (based on newly gnosed patients, 20	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	♦ 0	34%	NCDR	2010
grag	8		161	53%	47%	58%	55%	43%	•	72%	NCDR	2010
sed p	9	······································	326	99%	97%	100%	92%	36%	•••	100%	NLCA	2011
(ba inos		Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011
diag		Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%		30%	NLCA	2011
		2 Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167 286	58% 87%	53% 83%	64% 90%	62% 89%	13%		80%	NLCA	2011
	13 14		200	81%	03%	90%	897	2%		100%	NLCA NCPR	2011 2010/11
Specialist Team	15 16 17	Peer review: Pro: Peer review: are Peer review: are Peer review: are			mbe		9%		Spine chart &	5		_ _
Throughput	19 20	Number and prop descriptions Number and prop (41)			es, a nara	ator	97 29 29		range of data			tes
and		2 Number and prop	+ ~		pare		9%	0%	•	79%	NLCA	2011
pathology		3 Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	779	52%		100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%	 O 	97%	HES	2011
	25	5 Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%		100%	CWT	2012/13 Q2
•	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%		100%	CWT	2012/13 Q2
Waiting times	27	7 Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%	•	46%	CWT	2011/12
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%	• •	100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	•	100%	NLCA	2011
	30		50	17%	13%	22%	16%	0%	•	38%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	00				21%	0.0/			NLCA	2011
Practice	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%		0%		45%	NLOA	2011
Practice	31 32 33	2 No. and proportion resected of patients (from #2) with confirmed NSCLC 3 No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease	48 40	48%	38%	59%	53%	0%	0+	100%	NLCA	2011
Practice	31 32 33	2 No. and proportion resected of patients (from #2) with confirmed NSCLC	48 40 27	48% 68%	38% 52%	59% 80%	53% 68%	0% 0%		100% 100%	NLCA NLCA	2011 2011
Practice	31 32 33 34 35	No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	48 40 27 28	48% 68% 58%	38% 52% 44%	59% 80% 71%	53% 68% 55%	0% 0% 0%		100% 100% 100%	NLCA NLCA NLCA	2011 2011 2011 2011
	31 32 33 34 35 36	No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments	48 40 27 28 23,053	48% 68% 58% 41%	38% 52% 44% 41%	59% 80% 71% 41%	53% 68%	0% 0% 0% 15%		100% 100% 100% 68%	NLCA NLCA NLCA PBR SUS	2011 2011 2011 2011 2011/12
Practice Outcomes and Recovery	31 32 33 34 35 36 37	No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality	48 40 27 28 23,053 176	48% 68% 58% 41% 0.95	38% 52% 44% 41% 0.82	59% 80% 71% 41% 1.11	53% 68% 55%	0% 0% 0% 15% 0.57		100% 100% 100% 68% 1.49	NLCA NLCA NLCA PBR SUS NLCA	2011 2011 2011 2011/12 2011/12
Outcomes and Recovery	31 32 33 34 35 36 37 38	No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with stage IIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	48 40 27 28 23,053 176 34%	48% 68% 58% 41% 0.95 1.43	38% 52% 44% 0.82 0.97	59% 80% 71% 41%	53% 68% 55% 32% 1.(1.(0% 0% 15% 0.57 0.40		100% 100% 100% 68% 1.49 2.67	NLCA NLCA NLCA PBR SUS NLCA NLCA	2011 2011 2011 2011/12 2011 2011 2011
Outcomes and Recovery Patient	31 32 33 34 35 36 37 38 39	No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with stage IIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year Patients surveyed & % reporting always being treated with respect & dignity (6)	48 40 27 28 23,053 176	48% 68% 58% 41% 0.95 1.43 n/a	38% 52% 44% 41% 0.82 0.97	59% 80% 71% 41% 1.11	53% 68% 55%	0% 0% 15% 0.57 0.40 66%		100% 100% 100% 68% 1.49 2.67 100%	NLCA NLCA PBR SUS NLCA NLCA CPES	2011 2011 2011 2011/12 2011 2011 2011 20
Outcomes and Recovery	31 32 33 34 35 36 37 38	No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and prop. of patients (from #2) with stage IIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year Patients surveyed & % reporting always being treated with respect & dignity (6) Number of survey questions and % of those questions scoring red and green (7)	48 40 27 28 23,053 176 34%	48% 68% 58% 41% 0.95 1.43	38% 52% 44% 41% 0.82 0.97	59% 80% 71% 41% 1.11	53% 68% 55% 32% 1.(1.(0% 0% 15% 0.57 0.40		100% 100% 100% 68% 1.49 2.67	NLCA NLCA NLCA PBR SUS NLCA NLCA	2011 2011 2011 2011/12 2011 2011 2011

Profile anatomy



		_	_			-				
		No. of	Percent	tage or rate		Irus	t rate or percentage compared to Eng	land		
Section	# Indicator	natients/	Lower 95% ust confidence limit		England	Low- est	Range	High- est	Source	Period
	1 Number of newly diagnosed lung cancer patients per year, 2010 [_				_	• •	588	NCDR	2010
Size	 Number of NLCA patients - lung cancer Number of NLCA patients - mesothelioma 	natie	nts d	liadn	OSE	be	• •	585	NLCA	2011
		patie		nagn	030	G u		31	NLCA	2011
-	5 Patients (from #1) with recorded ethnicity	295	97% 94%	% 98%	93%	66%	• •	100%	NCDR	2010
2010	6 Patients (from #5) with recorded ethnicity which is not White-British	2001	01701 047			0%	•	46%	NCDR	2010
Demographics (based on newly gnosed patients, 2010)	7 Patients (from #1) who are Income Deprived (2) 8 Male patients (from #1) Patients (from #1)	t dem	odra	nhic	S	7%	◆ 0	34%	NCDR	2010
Jrap on n atiei		u dem	ogra	Pine	-	43%	0 🔶	72%	NCDR	2010
mog sed p	 Number and proportion of patients (from #2) with a stage assigned Number and proportion of patients, excluding SCLC, with stage I or II assign In the stage of th	dina	etaac	/DC	é	36%	•••	100%	NLCA	2011
De (ba gnos	10 Number and proportion of patients, excluding SCLC, with stage I or II assign 11 Number and proportion of patients, excluding SCLC, with a stage IIIA assign	ung	Slaye	3/23)		10% 4%	••	68% 30%	NLCA NLCA	2011 2011
dia	12 Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58% 53%	% 64%	62%	13%	•	80%	NLCA	2011
	13 Proportion of patients (from #2) with a Performance Status assigned	286	87% 839	90%	89%	2%		100%	NLCA	2011
	14 Peer review: Does the specialist team have full membershin? (3)	67	Vae				I		NCPR	2010/11
Specialist	¹⁵ Personalist toom Door Dovi								NCPR	2010/11
Team	Specialist team – Peer Revi	ew cc	ncer	'ns a	na		S coverage		NCPR	2010/11
	1/ Pe 18 Number and properties of actients (from #2) seen by CNS (5)								NCPR	2010/11
		206	63% 57%	68%	79%	0%		100%	NICA	2011
	19 Number of urgent GP referrals for suspected cancer	406	63% 57%	68%	79% 293	0%		853	CWT	2011 2010/11
Throughput	20 Number and proportion of pati		63% 57%	68%		0%	•	853 93%		
Throughput and	20 Number and proportion of pati		63% 57°				akdown	100%	CWT NLCA NLCA	2010/11 2011 2011
- · ·	 Number and proportion of pati 		<u>570</u> J y – k			orea	akdown	100% 79%	CWT NLCA NLCA NLCA	2010/11 2011 2011 2011
and	 Number and proportion of pati 						akdown	100%	CWT NLCA NLCA NLCA NLCA	2010/11 2011 2011 2011 2011 2011
and	 Number and proportion of pati 		Jy - p 47% 409			0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	akdown	100% 79%	CWT NLCA NLCA NLCA NLCA HES	2010/11 2011 2011 2011 2011 2011 2011
and	 Number and proportion of pati Number and proportion of tamours with emergency presentations [experimental] Estimated proportion of tumours with emergency presentations [experimental] G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 20 	holog 94 135	47% 40% 96% 92%	% 54% % 98%	nt k	2% 88%	•	100% 79%	CWT NLCA NLCA NLCA NLCA	2010/11 2011 2011 2011 2011 2011
and	 Number and proportion of pati Number and proportion of tamours with emergency presentations [experimental] Estimated proportion of tumours with emergency presentations [experimental] G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 20 	holog 94 135	47% 40% 96% 92%	% 54% % 98%	nt k	2% 88%	•	100% 79%	CWT NLCA NLCA NLCA NLCA HES CWT	2010/11 2011 2011 2011 2011 2011 2011 20
and pathology	 Number and proportion of pati Number and proportion of tumours with emergency presentations [experimental] G22 2012/13: Urgent GP referrat for suspected cancer seen within 2 weeks G22 2012/13: Urgent GP referrat for suspected cancer seen within 2 weeks G22 2012/13: Urgent GP referrat for suspected cancer seen within 2 weeks G22 2012/13: Urgent GP referrat for suspected cancer seen within 2 weeks 	holog 94 135	47% 40% 96% 92%	% 54% % 98%	nt k	2% 88%	•	100% 79%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT	2010/11 2011 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2012/13 Q2 2011/12
and pathology	 Number and proportion of pati Sumber and proportion of pati Sumption of pati Sumption of pati Sumber and proportion of pati Sumption of pati Sumption of pati Sumption of patients Sumptio	holog 94 135	47% 40% 96% 92% CONV	% 54% % 98% /ersi(nt k 37% 97%	2% 88%	•	100% 79% 100% 97% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2011/12 2012/13 Q2
and pathology	 Number and proportion of pati Number and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy 	holog 94 135	47% 40% 96% 92%	% 54% % 98% /ersi(nt k 37% 97% on/ 99%	2% 88% det 91%	•	100% 79% 100% 97% 100%	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT CWT	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2011/12 2012/13 Q2 2011/12
and pathology Waiting times	 Number and proportion of pati Stimated proportion of tumours with emergency presentations [experimental] G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 201 Urgen Cases G2 201/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion or resected of patients (from #2) excluding confirmed SCLC 	holog 94 1351 e and	47% 409 96% 92% CONV 00% 78% 53% 479	% 54% % 98% /ersic % 100% % 58% %	nt k 37% 97% on/ 50% 16%	2% 88% det 91% 36% 0%	•	100% 79% 100% 97% 100%	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT NLCA	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2012/13 Q2 2011/12 2012/13 Q2 2011 2011
and pathology	 Number and proportion of pati Stimated proportion of tumours with emergency presentations [experimental] G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 201 Urgen Cases G2 201/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion or resected of patients (from #2) excluding confirmed SCLC 	holog 94 1351 e and	47% 409 96% 92% CONV 00% 78% 53% 479	% 54% % 98% /ersic % 100% % 58% %	nt k 37% 97% on/ 99%	2% 88% det 91%	•	100% 79% 100% 97% 100%	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT CWT	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2011/12 2012/13 Q2 2011/12
and pathology Waiting times	 Number and proportion of pati Stimated proportion of tumours with emergency presentations [experimental] G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 201 Urgen Cases G2 201/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion or resected of patients (from #2) excluding confirmed SCLC 	holog 94 135	47% 409 96% 92% CONV 00% 78% 53% 479	% 54% % 98% /ersic % 100% % 58% %	37% 37% 97% 0 n/ 50% 16% 21%	2% 88% det 91% 36% 0%	•	100% 79% 100% 97% 100% 100% 38% 45%	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT NLCA NLCA	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2011/12 2012/13 Q2 2011/12 2012/13 Q2 2011 2011 2011
and pathology Waiting times	20 Number and proportion of pati 21 Number and proportion of pati 22 Number and proportion of pati 23 Number and proportion of pati 24 Number and proportion of pati 25 Mumber and proportion of pati 26 Number and proportion of pati 27 Urgen 26 Waiting times performance 27 Urgen 20 Q2 2012/13: First treatment began within 31 days or decision to treat 28 Gases 20 Q2 2012/13: First treatment began within 31 days or decision to treat 20 No. and proportion resected of patients (from #2) excluding confirmed SCLC 29 No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and I 30 No. and proportion of patients (from #2) with confirmed SCLC receiving cherrotherapy 31 No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and I 32 No. and proportion of patients (from #2) with confirmed SCLC receiving cherrotherapy 33 No. and proportion of patients (from #2) with confirmed SCLC receiving cherrotherapy 34 No. and proportion of patients (from #2) with confirmed SCLC receiving cherrotherapy	holog 94 1351 e and	47% 409 96% 92% CONV 00% 78% 53% 479	% 54% % 98% /ersic % 100% % 58% %	37% 37% 97%1 000/ 00% 16% 21% 53%	2% 88% det 91% 36% 0% 0%	•	100% 79% 100% 97% 100% 100% 38% 45% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT CWT CWT NLCA NLCA	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2012/13 Q2 2011/12 2012/13 Q2 2011/12 2012/13 Q2 2011 2011 2011 2011 2011 2011 2011
and pathology Waiting times	 Number and proportion of pati Number and proportion of pati Number and proportion of pati Throughput and proportion of pati Number and proportion of pati Throughput and proportion of pati Stimated proportion of pati Estimated proportion of pati Stimated proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC No. and proportion of patients (from #2), excluding confirmed SCLC No. and proportion of patients (from #2), excluding confirmed SCLC No. and proportion of patients (from #2), excluding confirmed SCLC No. and proportion of patients (from #2), excluding confirmed SCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy 		47% 40% 47% 40% 98% 92% CONV 8% 53% 47% bracti 53% 53% 47% bracti 6% 52% 44%	% 54% % 98% /ersic % /ersic % /ersic % /ersic % /ersic % //ersic %	37% 37% 97%1 000/ 00% 16% 21% 53%	2% 88% det 91% 36% 0% 0%	•	100% 79% 100% 97% 100% 38% 45% 100% 38% 45% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT CWT CWT CWT CWT	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2012/13 Q2 2011/12 2011/12 2011 2011 2011 2011 20
and pathology Waiting times Practice	 Number and proportion of pati Throughput and patient Statistical proportion of patients Estimated proportion of the patients G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) with confirmed SCLC No. and proportion resected of patients (from #2) with confirmed SCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of allow and adjusted hazard ratio for mortal Ano and proportion of allow and adjusted hazard ratio for mortal 		47% 40% 47% 40% 98% 92% CONV 8% 53% 47% bracti 53% 53% 47% bracti 6% 52% 44%	% 54% % 98% /ersic % /ersic % /ersic % /ersic % /ersic % //ersic %	37% 37% 97%1 000/ 00% 16% 21% 53%	2% 88% det 91% 36% 0% 0%	ection rates	100% 79% 100% 97% 100% 38% 45% 100% 100% 100% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA PBR SUS NLCA	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2011/12 2011/12 2011 2011 2011
and pathology Waiting times Practice Outcomes and Recovery	 Number and proportion of pati Number and proportion of pati Number and proportion of pati Throughput and proportion of pati Number and proportion of pati Number and proportion of pati Standard Proportion of pati Throughput and proportion of pati Standard Proportion of Patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and proportion of patients (from #2) with confirmed SCLC (with stage I and I) No. and pr		47% 40% 47% 40% 98% 92% CONV 8% 53% 47% bracti 53% 53% 47% bracti 6% 52% 44%	% 54% % 98% /ersic % /ersic % /ersic % /ersic % /ersic % //ersic %	37% 37% 97%1 000/ 00% 16% 21% 53%	2% 88% det 36% 0% 0% 0%	ection rates	100% 79% 100% 97% 100% 38% 45% 100% 38% 45% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2011/12 2011/12 2011 2011 2011
and pathology Waiting times Practice Outcomes	 Number and proportion of pati Throughput and patient Statistical proportion of patients Estimated proportion of the patients G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks G2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) with confirmed SCLC No. and proportion resected of patients (from #2) with confirmed SCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy Ano. and proportion of allow and adjusted hazard ratio for mortal Ano and proportion of allow and adjusted hazard ratio for mortal 	holog 94 135 e and 141 174 nical p 5 and	CONV CONV 53% 47% practi reco	×ersic ×ersic ×ersic ×ersic ×ersic × × × × × × × × × × × × ×	37% 37% 97%1 000/ 00% 16% 21% 53%	2% 88% det 91% 36% 0% 0%	ection rates	100% 79% 100% 97% 100% 38% 45% 100% 100% 100% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA PBR SUS NLCA	2010/11 2011 2011 2011 2011 2012/13 Q2 2012/13 Q2 2011/12 2011/12 2011/12 2011 2011 2011

Profiles overview



Using information to improve quality & choice

- Contains many relevant process, clinical, and outcome indicators – but new data gives new opportunities
- Profile format is strong at assessing and

benchmarking organisations (but not the whole story)



Cancer Outcomes Conference 9 & 10 June 2014 Hilton Birmingham Metropole

www.ncin.org.uk/conference



The Cancer Outcomes Conference 2014 will explore the 'power of information' both locally and nationally.

It will examine how UK-wide cancer registration data and other health related datasets are being exploited to reduce cancer incidence, mortality and morbidity.

To find out more, visit <u>www.ncin.org.uk/conference</u>







Using information to improve quality & choice

nickycoombes@nhs.net

020 7654 8148 www.ncin.org.uk